Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 3Classical hematology 2Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Neoplasms 2Burns 2Anemia, Sickle Cell 2Pain 1Breakthrough Pain 1Agnosia 1

Interventions

Epoetin Alfa 25Darbepoetin alfa 17apixaban 9Rivaroxaban 9Dalteparin 7Heparin, Low-Molecular-Weight 6Surveys and Questionnaires 5Meropenem 5fludarabine phosphate 4Vancomycin 4Tinzaparin 4Enoxaparin 4Cyclosporine 4Cefepime 4ferric carboxymaltose 3edoxaban 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Ceftazidime 3Carboplatin 3Busulfan 3Antilymphocyte Serum 3Amikacin 3romiplostim 2peginesatide 2hematide 2fludarabine 2epoetin beta 2bemiparin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Fentanyl × Classical hematology × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡